Revolution Medicines (NASDAQ:RVMD) Stock Keeps Buy Rating at HC Wainwright

Revolution Medicines logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright reaffirmed its Buy rating on Revolution Medicines and set a $350 price target, implying 109.74% upside from the prior close.
  • Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus rating and an average price target of $262.75.
  • Revolution Medicines reported quarterly EPS of -$1.90, better than analysts’ -$2.35 estimate, and revenue of $197.56 million versus expectations of $25.58 million.
  • Interested in Revolution Medicines? Here are five stocks we like better.

Revolution Medicines (NASDAQ:RVMD - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $350.00 price objective on the stock. HC Wainwright's target price indicates a potential upside of 109.74% from the stock's previous close.

A number of other brokerages have also recently commented on RVMD. Bank of America reduced their target price on shares of Revolution Medicines from $265.00 to $264.00 and set a "buy" rating for the company in a research report on Friday, October 9th. Oppenheimer boosted their price target on shares of Revolution Medicines from $230.00 to $260.00 and gave the stock an "outperform" rating in a research report on Thursday, August 27th. The Goldman Sachs Group started coverage on shares of Revolution Medicines in a research note on Thursday, September 24th. They set a "buy" rating and a $267.00 price objective for the company. Royal Bank Of Canada upped their price objective on shares of Revolution Medicines from $260.00 to $321.00 and gave the company an "outperform" rating in a research note on Thursday, November 5th. Finally, Evercore reiterated an "outperform" rating and issued a $320.00 price objective on shares of Revolution Medicines in a report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $262.75.

Check Out Our Latest Stock Report on Revolution Medicines

Revolution Medicines Stock Down 3.1%

NASDAQ RVMD opened at $166.87 on Tuesday. The business has a fifty day moving average price of $193.60 and a 200 day moving average price of $159.77. Revolution Medicines has a one year low of $67.27 and a one year high of $224.31. The company has a debt-to-equity ratio of 0.44, a quick ratio of 8.34 and a current ratio of 8.36. The company has a market cap of $36.09 billion, a P/E ratio of -18.32 and a beta of 1.44.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, beating analysts' consensus estimates of ($2.35) by $0.45. The firm had revenue of $197.56 million during the quarter, compared to analysts' expectations of $25.58 million. During the same quarter in the previous year, the business posted ($1.61) EPS. Research analysts anticipate that Revolution Medicines will post -7.41 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Mark Goldsmith sold 80,000 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $209.20, for a total value of $16,736,000.00. Following the completion of the sale, the insider owned 267,330 shares of the company's stock, valued at $55,925,436. This represents a 23.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Elizabeth Anderson sold 10,143 shares of the firm's stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the sale, the director owned 4,333 shares of the company's stock, valued at $836,442.32. This represents a 70.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 326,741 shares of company stock worth $66,147,340 over the last ninety days. 7.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Revolution Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Burkett Financial Services LLC purchased a new stake in Revolution Medicines in the third quarter valued at $27,000. Contravisory Investment Management Inc. acquired a new position in shares of Revolution Medicines in the 2nd quarter valued at $32,000. Johnson Financial Group Inc. acquired a new position in shares of Revolution Medicines in the 2nd quarter valued at $37,000. Silvant Capital Management LLC purchased a new position in shares of Revolution Medicines during the 2nd quarter worth $41,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of Revolution Medicines during the 2nd quarter worth $41,000. Institutional investors and hedge funds own 94.34% of the company's stock.

Revolution Medicines Company Profile

(Get Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company's research centers on RAS proteins, which can contribute to the growth of many cancers. The company's pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

Featured Articles

Analyst Recommendations for Revolution Medicines (NASDAQ:RVMD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Revolution Medicines Right Now?

Before you consider Revolution Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revolution Medicines wasn't on the list.

While Revolution Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines